Abstract | BACKGROUND: METHODS: ASPC-1 cells were grown to 70% to 80% confluence in 20% fetal calf serum-RPMI. Medium was changed to serum free. TGF-beta 1 was added at concentrations of 0, 1, 5, and 10 ng/mL with or without plasminogen activator inhibitor type-1 (PAI-1) at concentrations of 0, 5, 10, 50, and 100 micrograms/mL. Cells were then cultured for an additional 24 hours. The serum-free conditioned medium was obtained. Angiostatin generation was determined by incubating 20 micrograms of plasminogen with 100 microL of serum-free conditioned medium for 0, 1, 2, 3, 6, 12, and 24 hours. Samples were run on 12% sodium dodecyl sulfate- polyacrylamide gel electrophoresis and transferred. The membrane was probed with a monoclonal antibody to the kringle 1-3 fragment of plasminogen and developed using enhanced chemiluminescence. RESULTS: CONCLUSIONS:
|
Authors | C A O'Mahony, D Albo, G P Tuszynski, D H Berger |
Journal | Surgery
(Surgery)
Vol. 124
Issue 2
Pg. 388-93
(Aug 1998)
ISSN: 0039-6060 [Print] United States |
PMID | 9706163
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies
- Antineoplastic Agents
- Peptide Fragments
- Plasminogen Activator Inhibitor 1
- Serine Proteinase Inhibitors
- Transforming Growth Factor beta
- Angiostatins
- Plasminogen
|
Topics |
- Adenocarcinoma
- Angiostatins
- Antibodies
(pharmacology)
- Antineoplastic Agents
(analysis, metabolism)
- Blotting, Western
- Dose-Response Relationship, Drug
- Humans
- Neovascularization, Pathologic
(enzymology, physiopathology)
- Pancreatic Neoplasms
- Peptide Fragments
(analysis, biosynthesis, metabolism)
- Plasminogen
(analysis, biosynthesis, metabolism)
- Plasminogen Activator Inhibitor 1
(immunology, pharmacology)
- Serine Proteinase Inhibitors
(immunology, pharmacology)
- Transforming Growth Factor beta
(pharmacology)
- Tumor Cells, Cultured
(drug effects, metabolism)
|